Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial
Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial
复制标题
DOI：
10.1097/qad.0b013e328340a1e7
复制
发表时间：
2011-01-02
期刊：
影响因子：
3.8
通讯作者：
Costagliola, Dominique
中科院分区：
文献类型：
--
作者：
Boue, Francois;Reynes, Jacques;Costagliola, Dominique
在一项III期试验中研究了结构化治疗中断（STIs）期间的干扰素- α给药。我们随机选择168例在联合抗逆转录病毒治疗下无法检测到的慢性HIV感染患者，分别接受或不接受a-干扰素治疗。在性传播感染后随访期间必须恢复治疗的患者数量在两组之间没有显着差异。低CD4最低点和高基线HIV-DNA的患者在干扰素组中恢复治疗的风险更高。
Interferon-alpha administration during structured treatment interruptions (STIs) was studied in a phase III trial. We randomized 168 chronically infected HIV undetectable under combined antiretroviral therapy patients to have three STIs with or without a-interferon. The number of patients who had to resume treatment during post-STI follow-up was not significantly different between the two arms. Patients with a low CD4 nadir and a high baseline HIV-DNA had a higher risk of treatment resumption in the interferon arm.